ArticleInnovation (Cambridge (Mass.))2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study.
Open access · goldAbstract read
In one paragraph
Article in Innovation (Cambridge (Mass.)), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Trial
- Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.Signal transduction and targeted therapy · 2024Trial
- Metabolic-inflammatory index CTI identifies high-risk early-stage natural killer/T-cell lymphoma and informs a novel prognostic model.Biomarker research · 2026Article
- Quercetin exerts radioprotective effects against radiation-induced intestinal injury with involvement of the PI3K-AKT/Caspase-3 axis.Molecular and cellular biochemistry · 2026Article
- Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.Blood advances · 2026Article
- Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.Blood advances · 2026Article
- Radiotherapy alone versus combined therapy in stage I natural killer/T-cell lymphoma: impact of local invasion on treatment outcomes.Clinical and experimental medicine · 2025Article
- Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma.The oncologist · 2025Article
- P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management.Frontiers in medicine · 2025Article
- Comparison of pegaspargase with concurrent radiationOncology research · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 8 institutions in 1 country.
Huijuan ZhongShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shu ChengShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Xi ZhangDepartment of Hematology, Xinqiao Hospital, Chongqing 400037, China.
Bing XuDepartment of Hematology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361009, China.
Jiayi ChenDepartment of Radiation Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Xufeng JiangDepartment of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Jie XiongShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Yu HuInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Guohui CuiInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Juying WeiDepartment of Hematology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China.
Wenbin QianDepartment of Hematology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Xiaobing HuangInstitute of Hematology, Department of Hematology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China.
Ming HouDepartment of Hematology, Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
Feng YanDepartment of Hematology, Third Affiliated Hospital of Suzhou University, First People's Hospital of Changzhou, Changzhou, Jiangsu 213004, China.
Xin WangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China.
Yongping SongDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450003, China.
Jianda HuFujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350401, China.
Yuanhua LiuDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu 210009, China.
Xuejun MaDepartment of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
Fei LiDepartment of Hematology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Chongyang WuDepartment of Hematology, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China.
Junmin ChenDepartment of Hematology and Rheumatology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350004, China.
Li YuDepartment of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330008, China.
Ou BaiDepartment of Hematology, First Hospital of Jilin University, Changchun, Jilin 130061, China.
Jingyan XuDepartment of Hematology, Nanjing Drum Tower Hospital, Nanjing, Jiangsu 210008, China.
Zunmin ZhuDepartment of Hematology, Henan Province People's Hospital, Zhengzhou, Henan 450003, China.
Li LiuDepartment of Hematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710032, China.
Xin ZhouDepartment of Hematology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, China.
Li HuangDepartment of Oncology and Hematology, Hospital Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, China.
Yin TongDepartment of Hematology, Shanghai General Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200080, China.
Ting NiuDepartment of Hematology, Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Depei WuFirst Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.
Hao ZhangDepartment of Otolaryngology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Chaofu WangDepartment of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Binshen OuyangDepartment of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Hongmei YiDepartment of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Qi SongDepartment of Radiology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Gang CaiDepartment of Radiation Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Biao LiDepartment of Nuclear Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Jia LiuDepartment of Hematology, Xinqiao Hospital, Chongqing 400037, China.
Zhifeng LiDepartment of Hematology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361009, China.
Rong XiaoInstitute of Hematology, Department of Hematology, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, China.
Luqun WangDepartment of Hematology, Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.
Yujie JiangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China.
Yanyan LiuDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450003, China.
Xiaoyun ZhengFujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350401, China.
Pengpeng XuShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Hengye HuangSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Li WangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Saijuan ChenShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Weili ZhaoShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Ruijin Hospital · CNShanghai Jiao Tong University · CNShanghai Institute of Hematology · CNShandong Provincial Hospital · CNUnion Hospital · CNFudan University Shanghai Cancer Center · CNNanchang University · CNSoochow University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate, etoposide, dexamethasone, and pegaspargase (MESA) with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type (NKTCL). We explored the efficacy and safety of reduced-intensity, non-intravenous etoposide, dexamethasone, and pegaspargase (ESA) with sandwiched radiotherapy. This multicenter, randomized, phase III trial enrolled patients aged between 14 and 70 years with newly diagnosed early-stage nasal NKTCL from 27 centers in China. Patients were randomly assigned (1:1) to receive ESA (pegaspargase 2,500 IU/m
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.